entertainment -WSS

entertainment

author：knowledge 2025-10-02 20:49:15 - browse：36

The ability of cancer cells to move and spread depends on actin-rich core structures such as the podosomes (yellow) shown here in melanoma cells. Cell nuclei (blue), actin (red), and an actin regulator (green) are also shown. — Metastatic melanoma cells Julio C. Valencia,/NCI Center for Cancer Research

Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from Iovance, is the first cell therapy approved for a solid tumor.

“It’s so exciting and gratifying,” said Allison Betof Warner, a cell therapy researcher and physician at Stanford University who has worked on Amtagvi. “This is a game-changing moment for our field. We’ve seen huge success of cellular therapy for hematologic malignancies, and we’ve yet to capitalize on that for solid tumors. This is hopefully the first of many to come.”

In a Phase 2 clinical trial, titled C-144-01, 153 patients who had already been on a median of three prior lines of therapy received lifileucel, and 31% of them responded to therapy. “These are in very late line patients. They’ve exhausted every standard care option,” Betof Warner said. “The most promising part of this therapy for me is that 42% of patients who responded were still responding for 18 months or longer. It’s truly incredible.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： In Spain, a hospital brews its own CAR

WSS

Grail spinoff by Illumina should end disastrous merger attempt

Medicare drug price negotiation hasn't dried up venture capital

Why health care costs have stayed mostly flat since 2010

RaDonda Vaught to speak at CommonSpirit event on patient safety

FogPharma raises $145 million in rare Series E round

RSV vaccines may be linked to small increased risk of developing GBS

hotspot

entertainment

leisure time

Psychedelics group wrestles with new pharma identity

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Cancer drug shortages should be causing more outrage

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Medicare proposal to cover medical devices draws a mixed reaction

In Spain, a hospital brews its own CAR

Sports medicine is finally prioritizing gender equality

CRISPR gene editing developments we’re watching in 2024

Bright Health sells Medicare Advantage business to Molina

How to keep neuroscience’s past racism from being its future

entertainment

Hospitals owned by private equity see complications spike 25%

International team creates first chimeric human

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

What STAT readers think about the FDA and patient advocacy

Can sheer will power keep patients alive in their dying hours?

Clinical trials giant ICON acquires HumanFirst

explore

entertainment

focus

hotspot